Dr. Mosley's Laboratory
Research Goals
Collaborators
Funding
Techniques
Personnel
Return to Dr. Mosley's home page
Dr. Mosley's biographical information

Research Goals

Develop vaccine strategies that induce and sustain anti-inflammatory T cell (Th2 or Th3) or regulatory T cell (Treg) responses, which interdict proinflammatory processes with subsequent amelioration of neurodegenerative processes and promotion of neuroprotection and/or neuroregeneration. These strategies for neuroprotective vaccines are proposed to preferentially mediate anti-inflammatory responses.


Collaborators

Howard E. Gendelman, Pharmacology and Experimental Neuroscience, UNMC, Omaha, NE
Michael Boska, Radiology, UNMC, Omaha, NE
Elena Batrakova, Pharmaceutical Sciences, UNMC, Omaha, NE
David George Standaert, Neurology, University of Alabama, Birmingham, AL
David McMillan, Pharmacology and Experimental Neuroscience, UNMC, Omaha, NE
JoEllyn McMillan, Pharmacology and Experimental Neuroscience, UNMC, Omaha, NE
Dong Wang, Pharmaceutical Sciences, UNMC, Omaha, NE 
Pawel Ciborowski, Pharmacology and Experimental Neuroscience, UNMC, Omaha, NE 
M.A. (Tony) Hollingsworth, Eppley Institute for Research in Cancer and Allied Diseases, Omaha, NE 
Joyce Solheim, Eppley Institute for Research in Cancer and Allied Diseases, Omaha, NE


Funding

NanoART Manufacture, Delivery and Pharmacokinetics for Optimizing Drug Adherence
PI: H.E. Gendelman; Co-I: R. L. Mosley
Source: NIH/NIDA P01DA028555
This is an integrative cross approach translational and multi-investigator program grant seeking to develop nanoformulated antiretroviral drug therapy from the bench to the patient.

Neuroprotective Immunity and HIV Dementia
PI: H. E. Gendelman; Co-I: R. L. Mosley
Source: NIH/NINDS 4R01NS034239
This proposal will determine cell responses in macrophages following HIV-1 infection and engagement with T cells and T cell subsets. Macrophage functions including phagocytosis, antigen presentation, intracellular killing and effector cell responses and their modulation by T cells is a focus for this work. Signal transduction pathways and mechanisms for virus-induced neurotoxicity or neuroprotection will be developed.

Microglial ion channels and HIV-1-associated dementia
PI: H. Xiong; Co-I: R. L. Mosley
Source: NIH/NINDS 4R01NS077873
This grant studies how HIV-1 triggers microglia activation, migration and production of neurotoxins via microglia ion channels, resulting in neuronal damage and ultimately neurological dysfunction.

Leukine (Sargramostim) for Parkinson's Disease
PI: H. E. Gendelman; Co-I: R. L. Mosley
Source: Sanofi U.S. Services, Inc.
These funds were in direct support for a randomized phase I study of Sargramostim in the treatment of Parkinson's disease. Safety and biomarker profiles were a primary research endpoint with clinical and immunological profiling advanced in the quest to improve treatment of motor skills sets during disease.

Nebraska Center for Nanomedicine
PI: T. Bronich; Co-I: R. L. Mosley
Source: 4P20GM103480-09
The program is an interdisciplinary Nanomedicine Center at the University of Nebraska Medical Center.  The focus of this program is to develop devices of nanoscale size to improve outcomes for cancer, neurodegenerative diseases, and cardiovascular diseases.

Preclinical Development of LBT-3627, a VPAC2 Agonist with Neuroprotective and Anti-inflammatory Activities in Parkinson's Disease
PI: H. E. Gendelman; Co-I: R. L. Mosley
Source: Michael J. Fox Foundation
The work focuses on establishing proof of concept for the drug LBT-3627 for treatment of Parkinson's disease.  We will perform dose and timed responses, evaluate regulatory T cell responses and neuroprotective activities in a range of animal models of human disease.

Parkinson's Technology
PI: H. E. Gendelman; Co-I: R. L. Mosley
Source: Moderna Therapeutics

Top of page


Techniques used in laboratory


Personnel

Charles Schutt
Graduate Student
cSchutt
Rebecca Wilshusen
Graduate Student
rWilshusen

Dr. Mosley's home page
Dr. Mosley's biographical Information
Top of page